Literature DB >> 36262501

A Rare Case of Pembrolizumab Associated Encephalopathy.

Sijan Basnet1, Rajanbir Singh2, Biswaraj Tharu3, Tushar Pawar4, Garima Basnet5.   

Abstract

We present a unique case of a 55-year-old man with confusion thought to be due to pembrolizumab which he was receiving for renal cell carcinoma. His workup for other possible etiologies for encephalopathy was negative. He was treated with high dose intravenous methylprednisolone followed by prednisone taper and intravenous immunoglobulin with gradual improvement in his mentation.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  Encephalopathy; Immune checkpoint inhibitors; Immune-related adverse events; Pembrolizumab

Year:  2022        PMID： 36262501      PMCID： PMC9529659          DOI： 10.55729/2000-9666.1091

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN： 2000-9666


  8 in total

Review 1.  Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

Authors:  Jeffrey S Weber; Michael Postow; Christopher D Lao; Dirk Schadendorf
Journal:  Oncologist       Date:  2016-07-08

Review 2.  Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.

Authors:  Sophie Feng; Jermaine Coward; Elizabeth McCaffrey; John Coucher; Paul Kalokerinos; Ken O'Byrne
Journal:  J Thorac Oncol       Date:  2017-08-24       Impact factor: 15.609

Review 3.  Management of toxicities of immune checkpoint inhibitors.

Authors:  Lavinia Spain; Stefan Diem; James Larkin
Journal:  Cancer Treat Rev       Date:  2016-02-06       Impact factor: 12.111

Review 4.  Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.

Authors:  Dimitri Psimaras; Roser Velasco; Cristina Birzu; Stefano Tamburin; Maryam Lustberg; Jordi Bruna; Andreas A Argyriou
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

5.  Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab.

Authors:  Dmitry Tchapyjnikov; Alexandra J Borst
Journal:  J Immunother       Date:  2017-09       Impact factor: 4.456

6.  Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.

Authors:  Kerry L Reynolds; Amanda C Guidon
Journal:  Oncologist       Date:  2018-11-27

7.  Severe neurologic complications of immune checkpoint inhibitors: a single-center review.

Authors:  Sarah Mancone; Thomas Lycan; Tamjeed Ahmed; Umit Topaloglu; Andrew Dothard; William J Petty; Roy E Strowd
Journal:  J Neurol       Date:  2018-05-14       Impact factor: 4.849

Review 8.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

Authors:  Claire F Friedman; Tracy A Proverbs-Singh; Michael A Postow
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.